人类 TSPO 配体 11C-DPA-713 的辐射剂量学和生物分布。
Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans.
机构信息
Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
出版信息
J Nucl Med. 2012 Feb;53(2):330-5. doi: 10.2967/jnumed.111.094565. Epub 2012 Jan 12.
UNLABELLED
Whole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for the assessment of translocator protein.
METHODS
Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding.
RESULTS
The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10(-2) mSv/MBq (7.43 × 10(-2) rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for (11)C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi).
CONCLUSION
(11)C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other (11)C-labeled PET tracers.
未加标签
全身 PET/CT 用于描述（11）C-DPA-713 的辐射剂量学，（11）C-DPA-713 是一种用于评估转位蛋白的特定 PET 配体。
方法
6 名健康对照者，3 名男性和 3 名女性，在静脉注射（11）C-DPA-713 后进行全身动态 PET 扫描。受检者从头部到大腿中部进行 7 次扫描，总共进行大约 100 分钟的 PET 采集。在有可见示踪剂摄取的器官中生成时间-活性曲线，并计算组织停留时间。使用 OLINDA 1.1 软件进行全身剂量计算，假设没有排尿。
结果
肺部、脾脏、肾脏和胰腺的吸收剂量最高。肺部被确定为剂量限制器官，平均吸收剂量为 2.01×10（-2）mSv/MBq（7.43×10（-2）rem/mCi）。根据美国食品和药物管理局联邦法规（21CFR361.1）中概述的暴露限制，（11）C-DPA-713 放射性示踪剂注射的单次剂量限制为 2,487.6 MBq（67.3 mCi）。
结论
（11）C-DPA-713 的摄取模式与转位蛋白的生物分布一致，产生的剂量负担与其他（11）C 标记的 PET 示踪剂相当。
Zotero 插件